Title:
ＦＯＸＰ３由来のペプチドに特異的なＴ細胞受容体様抗体
Document Type and Number:
Japanese Patent JP7022067
Kind Code:
B2
Abstract:
The presently disclosed subject matter provides antigen-binding proteins (e.g., chimeric antigen receptors) and antibodies or antigen-binding portions thereof that bind to a Foxp3 peptide/MHC molecule complex. Such antibodies, fusion proteins and conjugates thereof are useful for inhibiting regulatory T cells and treating cancers.
Inventors:
Schaumburg, David A.
Dao, Tao
Liu, Chen
Dao, Tao
Liu, Chen
Application Number:
JP2018536458A
Publication Date:
February 17, 2022
Filing Date:
January 13, 2017
Export Citation:
Assignee:
Memorial Sloan Kettering Cancer Center
Eureka Therapeutics, Incorporated
Eureka Therapeutics, Incorporated
International Classes:
C12N15/13; A61K35/76; A61K38/02; A61K39/395; A61K45/00; A61K45/06; A61K47/55; A61K47/68; A61K51/10; A61P35/00; A61P35/02; A61P37/04; A61P43/00; C07K14/47; C07K14/725; C07K16/18; C07K19/00; C12N1/15; C12N1/19; C12N1/21; C12N5/10; C12N15/12; C12N15/62; C12N15/63; G01N33/48; G01N33/53; G01N33/574
Domestic Patent References:
| JP2010514669A | ||||
| JP2013516494A |
Foreign References:
| US20100143359 |
Attorney, Agent or Firm:
Shusaku Yamamoto
Morishita Natsuki
Morishita Natsuki